Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS

Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr 21, 2026-

Roche’s multiple sclerosis pill delays relapse, but liver toxicity could need monitoring

Roche’s multiple sclerosis pill more than doubled patients’ relapse-free interval compared with Sanofi’s marketed MS pill Aubagio, according to data presented late on Tuesday. The drug, a BTK inhibitor called fenebrutinib, demonstrated “the lowest relapse ...

Roche’s experimental pill held MS relapses to about one every 17 years

Two Phase III studies beat teriflunomide and cut new or enlarging T2 brain lesions by up to 82.5%, strengthening Roche’s case for regulatory filings.